These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 22366055)

  • 1. Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice.
    Nietupski JB; Pacheco JJ; Chuang WL; Maratea K; Li L; Foley J; Ashe KM; Cooper CG; Aerts JM; Copeland DP; Scheule RK; Cheng SH; Marshall J
    Mol Genet Metab; 2012 Apr; 105(4):621-8. PubMed ID: 22366055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.
    Ashe KM; Bangari D; Li L; Cabrera-Salazar MA; Bercury SD; Nietupski JB; Cooper CG; Aerts JM; Lee ER; Copeland DP; Cheng SH; Scheule RK; Marshall J
    PLoS One; 2011; 6(6):e21758. PubMed ID: 21738789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholesterol-dependent increases in glucosylceramide synthase activity in Niemann-Pick disease type C model cells: Abnormal trafficking of endogenously formed ceramide metabolites by inhibition of the enzyme.
    Hashimoto N; Matsumoto I; Takahashi H; Ashikawa H; Nakamura H; Murayama T
    Neuropharmacology; 2016 Nov; 110(Pt A):458-469. PubMed ID: 27539961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.
    Davidson CD; Ali NF; Micsenyi MC; Stephney G; Renault S; Dobrenis K; Ory DS; Vanier MT; Walkley SU
    PLoS One; 2009 Sep; 4(9):e6951. PubMed ID: 19750228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential of histone deacetylase inhibitors in Niemann - Pick type C disease.
    Maceyka M; Milstien S; Spiegel S
    FEBS J; 2013 Dec; 280(24):6367-72. PubMed ID: 23992240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Niemann-Pick disease type C in two children with miglustat: initial responses and maintenance of effects over 1 year.
    Chien YH; Lee NC; Tsai LK; Huang AC; Peng SF; Chen SJ; Hwu WL
    J Inherit Metab Dis; 2007 Oct; 30(5):826. PubMed ID: 17603755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical role for glycosphingolipids in Niemann-Pick disease type C.
    Zervas M; Somers KL; Thrall MA; Walkley SU
    Curr Biol; 2001 Aug; 11(16):1283-7. PubMed ID: 11525744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.
    McEachern KA; Fung J; Komarnitsky S; Siegel CS; Chuang WL; Hutto E; Shayman JA; Grabowski GA; Aerts JM; Cheng SH; Copeland DP; Marshall J
    Mol Genet Metab; 2007 Jul; 91(3):259-67. PubMed ID: 17509920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport.
    te Vruchte D; Lloyd-Evans E; Veldman RJ; Neville DC; Dwek RA; Platt FM; van Blitterswijk WJ; Sillence DJ
    J Biol Chem; 2004 Jun; 279(25):26167-75. PubMed ID: 15078881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing GBA2 Activity Ameliorates Neuropathology in Niemann-Pick Type C Mice.
    Marques AR; Aten J; Ottenhoff R; van Roomen CP; Herrera Moro D; Claessen N; Vinueza Veloz MF; Zhou K; Lin Z; Mirzaian M; Boot RG; De Zeeuw CI; Overkleeft HS; Yildiz Y; Aerts JM
    PLoS One; 2015; 10(8):e0135889. PubMed ID: 26275242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study.
    Patterson MC; Vecchio D; Prady H; Abel L; Wraith JE
    Lancet Neurol; 2007 Sep; 6(9):765-72. PubMed ID: 17689147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity.
    Marshall J; Nietupski JB; Park H; Cao J; Bangari DS; Silvescu C; Wilper T; Randall K; Tietz D; Wang B; Ying X; Leonard JP; Cheng SH
    Mol Ther; 2019 Aug; 27(8):1495-1506. PubMed ID: 31208914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis.
    Elliot-Smith E; Speak AO; Lloyd-Evans E; Smith DA; van der Spoel AC; Jeyakumar M; Butters TD; Dwek RA; d'Azzo A; Platt FM
    Mol Genet Metab; 2008 Jun; 94(2):204-11. PubMed ID: 18387328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of a child diagnosed with Niemann-Pick disease type C with miglustat: a case report in Brazil.
    Santos ML; Raskin S; Telles DS; Löhr A; Liberalesso PB; Vieira SC; Cordeiro ML
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S357-61. PubMed ID: 18937049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early miglustat therapy in infantile Niemann-Pick disease type C.
    Di Rocco M; Dardis A; Madeo A; Barone R; Fiumara A
    Pediatr Neurol; 2012 Jul; 47(1):40-3. PubMed ID: 22704015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GCase and LIMP2 Abnormalities in the Liver of Niemann Pick Type C Mice.
    van der Lienden MJC; Aten J; Marques ARA; Waas ISE; Larsen PWB; Claessen N; van der Wel NN; Ottenhoff R; van Eijk M; Aerts JMFG
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33802460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.
    Butters TD; Dwek RA; Platt FM
    Glycobiology; 2005 Oct; 15(10):43R-52R. PubMed ID: 15901676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic administration of 2-hydroxypropyl-β-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function.
    Lopez AM; Terpack SJ; Posey KS; Liu B; Ramirez CM; Turley SD
    Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):780-7. PubMed ID: 25115571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gpnmb Is a Potential Marker for the Visceral Pathology in Niemann-Pick Type C Disease.
    Marques AR; Gabriel TL; Aten J; van Roomen CP; Ottenhoff R; Claessen N; Alfonso P; Irún P; Giraldo P; Aerts JM; van Eijk M
    PLoS One; 2016; 11(1):e0147208. PubMed ID: 26771826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of an anti-tumor necrosis factor therapeutic in a mouse model of Niemann-Pick C liver disease.
    Vincent M; Sayre NL; Graham MJ; Crooke RM; Shealy DJ; Liscum L
    PLoS One; 2010 Sep; 5(9):e12941. PubMed ID: 20886067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.